Transcriptome Analysis Reveals the Molecular Immunological Characteristics of Lesions in Patients with Halo Nevi When Compared to Stable Vitiligo, Normal Nevocytic Nevi and Cutaneous Melanoma

References

• Barona MI, Arrunategui A, Falabella R, Alzate A. An epidemiologic case-control study in a population with vitiligo. J Am Acad Dermatol. 1995;33(4):621–625. doi:10.1016/0190-9622(95)91282-7
   PubMed Web of Science ®Google Scholar
• Zeff RA, Freitag A, Grin CM, Grant-Kels JM. The immune response in halo nevi. J Am Acad Dermatol. 1997;37(4):620–624. doi:10.1016/S0190-9622(97)70181-6
   PubMed Web of Science ®Google Scholar
• Ding GZ, Zhao WE, Li X, Gong QL, Lu Y. A comparative study of mitochondrial ultrastructure in melanocytes from perilesional vitiligo skin and perilesional halo nevi skin. Arch Dermatol Res. 2015;307(3):281–289. doi:10.1007/s00403-015-1544-4
   PubMed Web of Science ®Google Scholar
• Speeckaert R, van Geel N. Distribution patterns in generalized vitiligo. J Eur Acad Dermatol Venereol. 2014;28(6):755–762. doi:10.1111/jdv.12171
   PubMed Web of Science ®Google Scholar
• Ezzedine K, Diallo A, Leaute-Labreze C, et al. Halo naevi and leukotrichia are strong predictors of the passage to mixed vitiligo in a subgroup of segmental vitiligo. Br J Dermatol. 2012;166(3):539–544. doi:10.1111/j.1365-2133.2011.10709.x
   PubMed Web of Science ®Google Scholar
• de Vijlder HC, Westerhof W, Schreuder GM, de Lange P, Claas FH. Difference in pathogenesis between vitiligo vulgaris and halo nevi associated with vitiligo is supported by an HLA association study. Pigment Cell Res. 2004;17(3):270–274. doi:10.1111/j.1600-0749.2004.00145.x
   PubMedGoogle Scholar
• Schallreuter KU, Kothari S, Elwary S, Rokos H, Hasse S, Panske A. Molecular evidence that halo in Sutton’s naevus is not vitiligo. Arch Dermatol Res. 2003;295(6):223–228. doi:10.1007/s00403-003-0427-2
   PubMed Web of Science ®Google Scholar
• Lerner AB. Part V: clinical applications of psoralens, and related materials: vitiligo. J Invest Dermatol. 1959;32(2):285–310. doi:10.1038/jid.1959.49
   PubMedGoogle Scholar
• Scherz-Shouval R, Elazar Z. ROS, mitochondria and the regulation of autophagy. Trends Cell Biol. 2007;17(9):422–427. doi:10.1016/j.tcb.2007.07.009
   PubMed Web of Science ®Google Scholar
• Cohen BE, Manga P, Lin K, Elbuluk N. Vitiligo and melanoma-associated vitiligo: understanding their similarities and differences. Am J Clin Dermatol. 2020;21(5):669–680. doi:10.1007/s40257-020-00524-0
   PubMed Web of Science ®Google Scholar
• Paradisi A, Tabolli S, Didona B, Sobrino L, Russo N, Abeni D. Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo. J Am Acad Dermatol. 2014;71(6):1110–1116. doi:10.1016/j.jaad.2014.07.050
   PubMed Web of Science ®Google Scholar
• Teulings HE, Overkamp M, Ceylan E, et al. Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners. Br J Dermatol. 2013;168(1):162–171. doi:10.1111/bjd.12111
   PubMed Web of Science ®Google Scholar
• Mochel MC, Ming ME, Imadojemu S, et al. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma. J Cutan Pathol. 2016;43(9):787–791. doi:10.1111/cup.12735
   PubMed Web of Science ®Google Scholar
• Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152(1):45–51. doi:10.1001/jamadermatol.2015.2707
   PubMed Web of Science ®Google Scholar
• Lommerts JE, Teulings HE, Ezzedine K, et al. Melanoma-associated leukoderma and vitiligo cannot be differentiated based on blinded assessment by experts in the field. J Am Acad Dermatol. 2016;75(6):1198–1204. doi:10.1016/j.jaad.2016.07.060
   PubMed Web of Science ®Google Scholar
• Houghton AN, Eisinger M, Albino AP, Cairncross JG, Old LJ. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med. 1982;156(6):1755–1766. doi:10.1084/jem.156.6.1755
   PubMed Web of Science ®Google Scholar
• Fishman P, Merimski O, Baharav E, Shoenfeld Y. Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo. Cancer-Am Cancer Soc. 1997;79(8):1461–1464.
   Google Scholar
• Garbelli S, Mantovani S, Palermo B, Giachino C. Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity? Pigment Cell Res. 2005;18(4):234–242. doi:10.1111/j.1600-0749.2005.00244.x
   PubMedGoogle Scholar
• Yuan X, Meng D, Cao P, et al. Identification of pathogenic genes and transcription factors in vitiligo. Dermatol Ther. 2019;32(5):e13025. doi:10.1111/dth.13025
   PubMed Web of Science ®Google Scholar
• Chiche L, Jourde-Chiche N, Whalen E, et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol. 2014;66(6):1583–1595. doi:10.1002/art.38628
   PubMed Web of Science ®Google Scholar
• Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74–84. doi:10.1016/S0140-6736(14)60763-7
   PubMed Web of Science ®Google Scholar
• Weyant GW, Chung CG, Helm KF. Halo nevus: review of the literature and clinicopathologic findings. Int J Dermatol. 2015;54(10):e433–e435. doi:10.1111/ijd.12843
   PubMed Web of Science ®Google Scholar
• Suh KY, Bolognia JL. Signature nevi. J Am Acad Dermatol. 2009;60(3):508–514. doi:10.1016/j.jaad.2008.10.056
   PubMed Web of Science ®Google Scholar
• Yang Y, Li S, Zhu G, et al. A similar local immune and oxidative stress phenotype in vitiligo and halo nevus. J Dermatol Sci. 2017;87(1):50–59. doi:10.1016/j.jdermsci.2017.03.008
   PubMed Web of Science ®Google Scholar
• Harris JE, Harris TH, Weninger W, Wherry EJ, Hunter CA, Turka LA. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin. J Invest Dermatol. 2012;132(7):1869–1876. doi:10.1038/jid.2011.463
   PubMed Web of Science ®Google Scholar
• Yu R, Broady R, Huang Y, et al. Transcriptome analysis reveals markers of aberrantly activated innate immunity in vitiligo lesional and non-lesional skin. PLoS One. 2012;7(12):e51040. doi:10.1371/journal.pone.0051040
   PubMed Web of Science ®Google Scholar
• Gill L, Zarbo A, Isedeh P, Jacobsen G, Lim HW, Hamzavi I. Comorbid autoimmune diseases in patients with vitiligo: a cross-sectional study. J Am Acad Dermatol. 2016;74(2):295–302. doi:10.1016/j.jaad.2015.08.063
   PubMed Web of Science ®Google Scholar
• Spritz RA, Andersen GH. Genetics of vitiligo. Dermatol Clin. 2017;35(2):245–255. doi:10.1016/j.det.2016.11.013
   PubMed Web of Science ®Google Scholar
• Wolff D, Lawitschka A. Chronic graft-versus-host disease. 2019:331–345.
   Google Scholar
• Bae JM, Choi KH, Jung HM, et al. Subsequent vitiligo after hematopoietic stem cell transplantation: a nationwide population-based cohort study from Korea. J Am Acad Dermatol. 2017;76(3):459–463. doi:10.1016/j.jaad.2016.08.064
   PubMed Web of Science ®Google Scholar
• Sanli H, Akay BN, Arat M, et al. Vitiligo after hematopoietic cell transplantation: six cases and review of the literature. Dermatology. 2008;216(4):349–354. doi:10.1159/000117705
   PubMed Web of Science ®Google Scholar
• Dou Y, Yim HC, Kirkwood CD, Williams BR, Sadler AJ. The innate immune receptor MDA5 limits rotavirus infection but promotes cell death and pancreatic inflammation. EMBO J. 2017;36(18):2742–2757. doi:10.15252/embj.201696273
   PubMed Web of Science ®Google Scholar
• Stratton R, Slapak G, Mahungu T, Kinloch-de LS. Autoimmunity and HIV. Curr Opin Infect Dis. 2009;22(1):49–56. doi:10.1097/QCO.0b013e3283210006
   PubMed Web of Science ®Google Scholar
• Lunemann JD, Frey O, Eidner T, et al. Increased frequency of EBV-specific effector memory CD8+ T cells correlates with higher viral load in rheumatoid arthritis. J Immunol. 2008;181(2):991–1000. doi:10.4049/jimmunol.181.2.991
   PubMed Web of Science ®Google Scholar